看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。3 O- J( N* G) `# _) t4 W! R
" m. f& f1 S: d+ b8 T* d, B+ }
$ ?- s# a; ?, s$ YCurrently available feasibility data for possible combination strategies. : t* |3 e% b, B# ^( N( d+ E9 R
————————————————————————————————# A4 Q6 @& C9 }, o
Combination Feasibility according to preliminary data 1 |! H z$ s+ @% s6 W
——————————————————————————————————) x( e! `( _5 C# ^6 ^7 y
Bevacizumab + sorafenib Yes, reduced dose
- u/ T" ^/ T, V0 _1 QBevacizumab + sunitinib† No
4 c; O' q2 J" u; gBevacizumab + temsirolimus Yes 4 z+ j( ~* r3 {; H3 J
Bevacizumab + everolimus Yes % Y" ?( q, w' l7 S5 e* n5 @
Sorafenib + sunitinib ? . I3 Y3 H+ e: t
Sorafenib + temsirolimus Yes, reduced dose
+ g: i+ {- E/ d9 j2 g V! a9 wSorafenib + everolimus Yes, reduced dose * L m2 V; p5 c+ z4 P/ \
Sunitinib + temsirolimus† No ' T# n- J8 F% b& V" e: Z' l
Sunitinib + everolimus ?
8 r$ n0 Q$ L3 e; `6 k, @Temsirolimus + everolimus ? 9 v, r) p, p+ T
————————————————————- Y% }0 E5 S1 |7 }0 |3 l9 ^! Z
†Led to US FDA warning.$ D' j6 D" {7 j+ h. O
?: As yet unattempted combination.2 ~* A" ~- C+ e0 G/ E1 V# P& |& w
|
显身卡
